logo-loader
viewArix Bioscience PLC

Arix Bioscience portfolio companies Autolus and Harpoon present updates at ASCO

Arix has a 6.45% stake in Autolus and 10.4% in Harpoon

Arix Bioscience PLC -
ASCO conference got underway on 29 May

Arix Bioscience PLC (LON:ARIX) has noted poster presentations from two of its portfolio companies at the Annual Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program that starts today.

Harpoon Therapeutics Inc (NASDAQ:HARP), presented interim data from the ongoing dose-escalation portion of a Phase 1 trial for HPN424 in patients with metastatic castration-resistant prostate cancer (mCRPC).

According to Harpoon, the initial safety data from the 44-patient trial showed that HPN424 is generally well-tolerated and cytokine-related adverse events have been transient and manageable.

Pharmacokinetic data supports weekly dosing and pharmacodynamic data supports T cell activation and target engagement consistent with the expected mechanism of action. 

Autolus Therapeutics PLC ( (NASDAQ: AUTL) announced new data highlighting progress on AUTO3, a CAR T cell therapy being investigated in a Phase 1/2 study in relapsed/refractory diffuse large B cell lymphoma (DLBCL).

According to Autolus, the data continues to show encouraging clinical activity alongside tolerable safety to deliver a potentially highly differentiated product profile

AUTO3 was well tolerated, with no patients experiencing dose-limiting toxicity, and there were no treatment-related deaths.

Arix has a 6.45% stake in Autolus and 10.4% in Harpoon.

Quick facts: Arix Bioscience PLC

Price: 86.5 GBX

LSE:ARIX
Market: LSE
Market Cap: £117.3 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Arix Bioscience PLC named herein, including the promotion by the Company of Arix Bioscience PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Arix Bioscience PLC: Proactive One2One Virtual Event

Arix Bioscience PLC's (LON:ARIX) Jonathan Tobin pitches the company to investors at the Proactive One2One Virtual Event. Arix is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting edge advances in life sciences.

3 weeks, 6 days ago

2 min read